Metformin is associated with improved left ventricular diastolic function measured by tissue Doppler imaging in patients with diabetes

European Journal of Endocrinology

Volumn 163, Issue 4, 2010, Pages 593-599

  Andersson, Charlotte ^a   Søgaard, Peter ^a   Hoffmann, Søren ^a   Hansen, Peter R ^a   Vaag, Allan ^b   Major Pedersen, Atheline ^a   Fritz Hansen, Thomas ^a   Bech, Jan ^a   Køber, Lars ^c   Torp Pedersen, Christian ^a   Gislason, Gunnar H ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b STENO DIABETES CENTER   (Denmark)

^c Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOOP DIURETIC AGENT; METFORMIN; SPIRONOLACTONE; SULFONYLUREA DERIVATIVE; THIAZIDE DIURETIC AGENT; ANTIDIABETIC AGENT;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ARTIFICIAL HEART PACEMAKER; COHORT ANALYSIS; DIABETES MELLITUS; DIABETIC PATIENT; DIASTOLE; DRUG USE; DYSLIPIDEMIA; ECHOCARDIOGRAPHY; FEMALE; HEART ATRIUM FIBRILLATION; HEART BUNDLE BRANCH BLOCK; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE RELAXATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TISSUE DOPPLER IMAGING; VALVULAR HEART DISEASE; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; MIDDLE AGED;

AGED; COHORT STUDIES; CORONARY ANGIOGRAPHY; DIABETES MELLITUS, TYPE 2; ECHOCARDIOGRAPHY; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; RETROSPECTIVE STUDIES; VENTRICULAR FUNCTION, LEFT;

EID: 77957170282     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-10-0624     Document Type: Article

References (34)

1. Kannel WB, Hjortland M & Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. American Journal of Cardiology 1974 34 29-34. (doi:10.1016/0002-9149(74)90089-7)
2. Andersson C, Weeke P, Pecini R, Kjaergaard J, Hassager C, Kober L & Torp-Pedersen C. Long-term impact of diabetes in patients hospitalized with ischemic and non-ischemic heart failure. Scandinavian Cardiovascular Journal 2009 44 37-44. (doi:10.3109/14017430903312438)
3. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C & Whelton PK. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Archives of Internal Medicine 2001 161 996-1002. (doi:10.1001/archinte.161.7.996) (Pubitemid 32295654)
4. Aneja A, Tang WH, Bansilal S, Garcia MJ & Farkouh ME. Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. American Journal of Medicine 2008 121 748-757. (doi:10.1016/j.amjmed.2008.03.046)
5. Witteles RM & Fowler MB. Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. Journal of the American College of Cardiology 2008 51 93-102. (doi:10.1016/j.jacc.2007.10.021)
6. Young ME, McNulty P & Taegtmeyer H. Adaptation and maladaptation of the heart in diabetes: part II: potential mechanisms. Circulation 2002 105 1861-1870. (doi:10.1161/01.CIR.0000012467.61045.87) (Pubitemid 34408899)
7. Rijzewijk LJ, van der Meer RW, Smit JWA, Diamant M, Bax JJ, Hammer S, Romijn JA, de Roos A & Lamb HJ. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. Journal of the American College of Cardiology 2008 52 1793-1799. (doi:10.1016/j.jacc.2008.07. 062)
8. From AM, Scott CG & Chen HH. The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction: a population-based study. Journal of the American College of Cardiology 2010 55 300-305. (doi:10.1016/j.jacc.2009.12.003)
9. Gundewar S, Calvert JW, Jha S, Toedt-Pingel I, Ji SY, Nunez D, Ramachandran A, Anaya-Cisneros M, Tian R & Lefer DJ. Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival in heart failure. Circulation Research 2009 104 403-411. (doi:10.1161/CIRCRESAHA.108.190918)
10. Sasaki H, Asanuma H, Fujita M, Takahama H, Wakeno M, Ito S, Ogai A, Asakura M, Kim J, Minamino T, Takashima S, Sanada S, Sugimachi M, Komamura K, Mochizuki N & Kitakaze M. Metformin prevents progression of heart failure in dogs: role of AMP-activated protein kinase. Circulation 2009 119 2568-2577. (doi:10.1161/CIRCULATIONAHA.108.798561)
11. Andersson C, Gislason G, Weeke P, Hoffmann S, Hansen P, Torp-Pedersen C & Sogaard P. Diabetes is associated with impaired myocardial performance in patients without significant coronary artery disease. Cardiovascular Diabetology 2010 9 3. (doi:10.1186/1475-2840-9-3)
12. Di Bonito P, Moio N, Cavuto L, Covino G, Murena E, Scilla C, Turco S, Capaldo B & Sibilio G. Early detection of diabetic cardiomyopathy: usefulness of tissue Doppler imaging. Diabetic Medicine 2005 22 1720-1725. (doi:10.1111/j.1464-5491.2005.01685.x)
13. Fang ZY, Schull-Meade R, Downey M, Prins J & Marwick TH. Determinants of subclinical diabetic heart disease. Diabetologia 2005 48 394-402. (doi:10.1007/s00125-004-1632-z) (Pubitemid 40543314)
14. Fang ZY, Yuda S, Anderson V, Short L, Case C & Marwick TH. Echocardiographic detection of early diabetic myocardial disease. Journal of the American College of Cardiology 2003 41 611-617. (doi:10.1016/S0735-1097(02) 02869-3)
15. Von Bibra H, Thrainsdottir IS, Hansen A, Dounis V, Malmberg K & Ryden L. Tissue Doppler imaging for the detection and quantitation of myocardial dysfunction in patients with type 2 diabetes mellitus. Diabetes & Vascular Disease Research 2005 2 24-30. (doi:10.3132/dvdr.2005.002) (Pubitemid 40333201)
16. Rakowski H, Appleton C, Chan KL, Dumesnil JG, Honos G, Jue J, Koilpillai C, Lepage S, Martin RP, Mercier LA, O'Kelly B, Prieur T, Sanfilippo A, Sasson Z, Alvarez N, Pruitt R, Thompson C & Tomlinson C. Canadian consensus recommendations for the measurement and reporting of diastolic dysfunction by echocardiography: from the Investigators of Consensus on Diastolic Dysfunction by Echocardiography. Journal of the American Society of Echocardiography 1996 9 736-760. (doi:10.1016/S0894-7317(96)90076-0)
17. Gaist D, Sorensen HT & Hallas J. The Danish prescription registries. Danish Medical Bulletin 1997 44 445-448.
18. Gislason GH, Rasmussen JN, Abildstrom SZ, Schramm TK, Hansen ML, Buch P, Sorensen R, Folke F, Gadsboll N, Rasmussen S, Kober L, Madsen M & Torp-Pedersen C. Persistent use of evidence-based pharmacotherapy in heart failure is associated with improved outcomes. Circulation 2007 116 737-744. (doi:10.1161/CIRCULATIONAHA.106.669101)
19. Morgan JP. Abnormal intracellular modulation of calcium as a major cause of cardiac contractile dysfunction. New England Journal of Medicine 1991 325 625-632. (doi:10.1056/NEJM199108293250906)
20. Andersen LJ, Hansen PR, Sogaard P, Madsen JK, Bech J & Krustrup P. Improvement of systolic and diastolic heart function after physical training in sedentary women. Scandinavian Journal of Medicine & Science in Sports 2010 20 50-57. (doi:10.1111/j.1600-0838.2009.01088.x)
21. Opdahl A, Remme EW, Helle-Valle T, Lyseggen E, Vartdal T, Pettersen E, Edvardsen T & Smiseth OA. Determinants of left ventricular early-diastolic lengthening velocity: independent contributions from left ventricular relaxation, restoring forces, and lengthening load. Circulation 2009 119 2578-2586. (doi:10.1161/CIRCULATIONAHA.108.791681)
22. Sohn DW, Chai IH, Lee DJ, Kim HC, Kim HS, Oh BH, Lee MM, Park YB, Choi YS, Seo JD & Lee YW. Assessment of mitral annulus velocity by Doppler tissue imaging in the evaluation of left ventricular diastolic function. Journal of the American College of Cardiology 1997 30 474-480. (doi:10.1016/S0735-1097(97) 88335-0)
23. Yalcin F, Kaftan A, Muderrisoglu H, Korkmaz ME, Flachskampf F, Garcia M & Thomas JD. Is Doppler tissue velocity during early left ventricular filling preload independent? Heart 2002 87 336-339. (doi:10.1136/heart.87.4.336)
24. Hoffmann S, Mogelvang R, Olsen NT, Sogaard P, Fritz-Hansen T, Bech J, Galatius S, Madsen JK & Jensen JS. Tissue Doppler echocardiography reveals distinct patterns of impaired myocardial velocities in different degrees of coronary artery disease. European Journal of Echocardiography 2010 11 544-549. (doi:10.1093/ejechocard/jeq015)
25. Hardie DG. AMP-activated protein kinase: the guardian of cardiac energy status. Journal of Clinical Investigation 2004 114 465-468. (doi:10.1172/ JCI22683)
26. Towler MC & Hardie DG. AMP-activated protein kinase in metabolic control and insulin signaling. Circulation Research 2007 100 328-341. (doi:10.1161/01.RES.0000256090.42690.05)
27. Nagueh SF, Rao L, Soto J, Middleton KJ & Khoury DS. Haemodynamic insights into the effects of ischaemia and cycle length on tissue Doppler-derived mitral annulus diastolic velocities. Clinical Science 2004 106 147-154. (doi:10.1042/CS20030204) (Pubitemid 38223433)
28. Topcu S, Tok D, Caliskan M, Ozcimen EE, Gullu H, Uckuyu A, Erdogan D, Zeyneloglu H & Muderrisoglu H. Metformin therapy improves coronary microvascular function in patients with polycystic ovary syndrome and insulin resistance. Clinical Endocrinology 2006 65 75-80. (doi:10.1111/j.1365-2265.2006. 02551.x)
29. van der Meer RW, Rijzewijk LJ, de Jong HWAM, Lamb HJ, Lubberink M, Romijn JA, Bax JJ, de Roos A, Kamp O, Paulus WJ, Heine RJ, Lammertsma AA, Smit JWA & Diamant M. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. Circulation 2009 119 2069-2077. (doi:10.1161/CIRCULATIONAHA. 108.803916)
30. Agarwal N, Rice SPL, Bolusani H, Luzio SD, Dunseath G, Ludgate M & Rees DA. Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial. Journal of Clinical Endocrinology and Metabolism 2010 95 722-730. (doi:10.1210/jc.2009-1985)
31. Jyothirmayi GN, Soni BJ, Masurekar M, Lyons M & Regan TJ. Effects of metformin on collagen glycation and diastolic dysfunction in diabetic myocardium. Journal of Cardiovascular Pharmacology and Therapeutics 1998 3 319-326. (doi:10.1177/107424849800300407) (Pubitemid 29131662)
32. Xiao H, Ma X, Feng W, Fu Y, Lu Z, Xu M, Shen Q, Zhu Y & Zhang Y. Metformin attenuates cardiac fibrosis by inhibiting the TGFβ1-Smad3 signaling pathway. Cardiovascular Research 2010 87 504-513. (doi:10.1093/cvr/ cvq066)
33. Khurana R & Malik IS. Metformin: safety in cardiac patients. Heart 2010 96 99-102. (doi:10.1136/hrt.2009.173773)
34. Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT & Johnson JA. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005 28 2345-2351. (doi:10.2337/diacare.28.10. 2345)